Pharmacological avantgarde and digital cardiology in the management of arterial hypertension

This scientific analysis systematizes modern strategies for controlling arterial hypertension (AH) through the prism of digital cardiology and innovative pharmacotherapy. Particular attention is paid to the undeniable prognostic priority of nocturnal blood pressure in verifying cardiovascular risk and the official legitimization by the ESH 2026 Consensus of wearable oscillometric devices with a built-in mechanical micro-cuff (in particular, Huawei Watch D2) for conducting daily ambulatory blood pressure monitoring. The consolidated position of leading international consortia (ESH, ESC, AHA/ACC) demonstrates skeptical realism regarding completely cuffless devices due to the unsatisfactory level of individual standard deviation and the risk of errors at night. Optimization of therapeutic management in the prima-ry care setting is based on overcoming clinical inertia through the implementation of the five-component A-B-C-D-E model, a team approach (Team-based care), an imperative start with fixed combinations and the integration into the treatment regimens of true resistant hypertension of the latest targeted molecules — dual endothelin receptor antagonists (ap-rocitentan), aldosterone synthase inhibitors (baxdrostat, lorundostat) and innovative long-acting RNA interference agents (zilebesiran) against the background of scientifically substantiated modification of the patient’s nutritional and locomotor profile.

References

1. Stergiou G. (2026) New ways to measure blood pressure: ready for clinical use? Conference presentation, ESC Congress 2026, Munich, Germany.
2. Staplin N., de la Sierra A., Ruilope L.M. et al. (2023) Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. Lancet, 401(10393): 2041–2050. doi: 10.1016/S0140-6736(23)00733-X.
3. Zhou Y., Zhang W., Wang X.Y. et al. (2025) Accuracy of a wearable watch-type oscillometric blood pressure monitor in rest and ambulatory blood pressure measurements. Hypertens Res., 48(11): 2961–2968. doi: 10.1038/s41440-025-02345-2.
4. Stergiou G.S., Menti A., Asayama K. et al. (2026) Wearable wrist-watch type cuff oscillometric blood pressure monitors: consensus statement by the European Society of Hypertension Working Group on blood pressure monitoring. Journal of Hypertension, 44(10): 1721–1731. doi: 10.1097/HJH.0000000000004415.
5. Kuwabara M., Harada K., Hishiki Y. et al. (2019) Validation of two watch-type wearable blood pressure monitors according to the ANSI/AAMI/ISO81060-2:2013 guidelines: Omron HEM-6410T-ZM and HEM-6410T-ZL. J. Clin. Hypertens. (Greenwich), 21(6): 853–858. doi: 10.1111/jch.13499.
6. Lunardi M., Muhammad F., Shahzad A. et al. (2024) Performance of wearable watch-type home blood pressure measurement devices in a real-world clinical sample. Clinical Research in Cardiology, 113(10): 1393–1404. doi: 10.1007/s00392-023-02353-7.
7. Zhang W., Zhou Y.N., Zhou Y. et al. (2022) Validation of the watch-type HUAWEI WATCH D oscillometric wrist blood pressure monitor in adult Chinese. Blood Press Monit., 27(5): 353–356. doi: 10.1097/MBP.0000000000000608.
8. Wang L., Xian H., Guo J. et al. (2022) A novel blood pressure monitoring technique by smart HUAWEI WATCH: a validation study according to the ANSI/AAMI/ISO 81060-2:2018 guidelines. Front. Cardiovasc. Med., 9: 923655. doi: 10.3389/fcvm.2022.923655.
9. Yi L., Lv Z.H., Hu S.Y. et al. (2022) Validating the accuracy of a multifunctional smartwatch sphygmomanometer to monitor blood pressure. J. Geriatr. Cardiol., 19(11): 843–852. doi: 10.11909/j.issn.1671-5411.2022.11.004.
10. Liu Y., Lu Y., Wu J. et al. (2025) Accuracy and reduced sleep disruption of a wearable smartwatch for nocturnal blood pressure monitoring: a validation study. J. Clin. Hypertens. (Greenwich), 27(11): e70183. doi: 10.1111/jch.70183.
11. Tomitani N., Kanegae H., Suzuki Y. et al. (2020) Stress-induced blood pressure elevation self-measured by a wearable watch-type device. Am. J. Hypertension, 34: 377–382.
12. Groppelli A., Rafanelli M., Testa G.D. et al. (2022) Feasibility of blood pressure measurement with a wearable (watch-type) monitor during impending syncopal episodes. J. Am. Heart Assoc., 11(16): e026420. doi: 10.1161/JAHA.122.026420.
13. Kario K., Shimbo D., Tomitani N. et al. (2020) The first study comparing a wearable watch-type blood pressure monitor with a conventional ambulatory blood pressure monitor on in-office and out-of-office settings. J. Clin. Hypertens., 22: 135–141.
14. Mukkamala R., Stergiou G.S., Avolio A.P. (2022) Cuffless blood pressure measurement. Ann. Rev. Biomed Eng., 24: 203–230. doi: 10.1146/annurev-bioeng-110220-014644.
15. Stergiou G.S., Avolio A.P., Palatini P. et al. (2023) European Society of Hypertension recommendations for the validation of cuffless blood pressure measuring devices: European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J. Hypertens., 41(12): 2074–2087. doi: 10.1097/HJH.0000000000003483.
16. Vybornova A., Polychronopoulou E., Wurzner-Ghajarzadeh A. et al. (2021) Blood pressure from the optical Aktiia Bracelet: a 1-month validation study using an extended ISO81060-2 protocol adapted for a cuffless wrist device. Blood Press Monit., 26(4): 305–311. doi: 10.1097/MBP.0000000000000531.
17. Mancia G., Kreutz R., Brunström M. et al. (2023) 2023 ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J. Hypertens., 41(12): 1874–2071. doi: 10.1097/HJH.0000000000003480.
18. McEvoy J.W., McCarthy C.P., Bruno R.M. et al. (2024) 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J., 45(38): 3912–4018. doi: 10.1093/eurheartj/ehae178.
19. Jones D.W., Ferdinand K.C., Taler S.J. et al. (2025) 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol., 86(18): 1567–1678. doi: 10.1016/j.jacc.2025.05.007.
20. Tang Y. (2026) Cuffless blood pressure measurements, artificial intelligence-based apps, and chatbots will become the mainstay of hypertension care: pro. Conference presentation, ESC Congress 2026, Munich, Germany.
21. Cohen J.B., Addo D.K., Jacobs J.A. et al. (2026) Impact of a smartwatch hypertension notification feature for population screening. JAMA, 335(11): 1001–1003. doi: 10.1001/jama.2025.26925.
22. Griffin A.C., Khairat S., Bailey S.C. et al. (2023) A chatbot for hypertension self-management support: user-centered design, development, and usability testing. JAMIA Open, 6(3): ooad073. doi: 10.1093/jamiaopen/ooad073.
23. Yang E. (2026) Cuffless blood pressure measurements, artificial intelligence-based apps, and chatbots will become the mainstay of hypertension care: con. Conference presentation, ESC Congress 2026, Munich, Germany.
24. Cohen J.B., Brady T.M., Juraschek S.P. et al. (2026) Apple Watch for hypertension screening. Hypertension, 83(2): e26031. doi: 10.1161/HYPERTENSIONAHA.125.26031.
25. De Pinho R. (2026) New blood pressure targets: how do we get there? Conference presentation, ESC Congress 2026, Munich, Germany.
26. Stolarz-Skrzypek K. (2026) Overview of new antihypertensive drugs. Conference presentation, ESC Congress 2026, Munich, Germany.
27. Schlaich M., Bellet M., Weber M. et al. (2022) Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. The Lancet, 400: 1927–1937.
28. Flack J.M., Azizi M., Brown J.M. et al. (2025) Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N. Engl. J. Med., 393(14): 1363–1374. doi: 10.1056/NEJMoa2507109.
29. Laffin LJ., Rodman D., Luther J.M. et al. (2023) Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial. JAMA, 330(12): 1140–1150. doi: 10.1001/jama.2023.16029.
30. Correa-Rotter R., Rossing P., Canziani M.E. et al. (2026) Post-hoc analysis on the effects of vicadrostat/empagliflozin by CKD severity/hypertension status. Kidney Int. Rep., 11(7): 106545. doi: 10.1016/j.ekir.2026.106545.
31. Verma S., Pradhan A., Thandi P. (2026) Zilebesiran: an RNA interference agent — its need and potential to transform hypertension treatment. Egypt Heart J., 78(1): 12. doi: 10.1186/s43044-026-00724-9.
32. Bakris G.L., Saxena M., Gupta A. et al. (2024) RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial. JAMA, 331(9): 740–749. doi: 10.1001/jama.2024.0728.
33. Desai A.S., Karns A.D., Badariene J. et al. (2025) Add-on treatment with zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial. JAMA, 334(1): 46–55. doi: 10.1001/jama.2025.6681.
34. Morosan P.A., Bobu A.M., Carauleanu A. et al. (2025) Zilebesiran as an innovative siRNA-based therapeutic approach for hypertension: emerging perspectives in cardiovascular medicine. Int. J. Mol. Sci., 26(21): 10717. doi: 10.3390/ijms262110717.
35. Alnylam Pharmaceuticals (2026) Zilebesiran in patients with hypertension not adequately controlled and with either established cardiovascular disease or high risk for cardiovascular disease (ZENITH) (ClinicalTrials.gov Registry No. NCT07181109). U.S. National Library of Medicine. ClinicalTrials.gov.
36. Charchar F. (2026) Overview of lifestyle interventions. Conference presentation, ESC Congress 2026, Munich, Germany.
37. World Health Organization (2023) Global report on hypertension: the race against a silent killer. World Health Organization.
38. Mertens E., Colizzi C., Peñalvo J.L. (2022) Ultra-processed food consumption in adults across Europe. Eur. J. Nutr., 61(3): 1521–1539. doi: 10.1007/s00394-021-02733-7.
39. Zhang X., Yuan Y., Li C. et al. (2024) Effect of a salt substitute on incidence of hypertension and hypotension among normotensive adults. J. Am. Coll. Cardiol., 83(7): 711–722. doi: 10.1016/j.jacc.2023.12.013.
40. Marcus G.M., Hu F.B., van Dam R.M. et al. (2026) Caffeine and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 154(9): e345–e355. doi: 10.1161/CIR.0000000000001454.
41. Hao W.R., Cheng C.Y., Chen H.Y. et al. (2024) The association between cafestol and cardiovascular diseases: a comprehensive review. Medicina (Kaunas), 60(6): 867. doi: 10.3390/medicina60060867.
42. World Health Organization (2020) Doing what matters in times of stress: an illustrated guide.
43. Bayoumy K., Gaber M., Elshafeey A. et al. (2021) Smart wearable devices in cardiovascular care: where we are and how to move forward. Nat. Rev. Cardiol., 18(8): 581–599. doi: 10.1038/s41569-021-00522-7.
44. Kario K., Schutte A., Touyz R. et al. (2026) The floor is yours: bring your questions on how to measure and monitor blood pressure in 2026 — expert panel. Panel presentation, ESC Congress 2026, Munich, Germany.